FDA Clearance Tracker · P050037-S028
RADIESSE INJECTABLE IMPLANT
Last checked: Nov 20, 2026Latest source record: Jun 20, 2012 (this decision)Source: openFDAMethods & limitations
Decided
Jun 20, 2012
Approved
Time to decision
448 days
Received Mar 30, 2011. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P050037-S028
- Device name
- RADIESSE INJECTABLE IMPLANT
- Applicant
- Merz North America, Inc.
- Applicant location
- Franksville, WI
- Received
- Mar 30, 2011
- Decided
- Jun 20, 2012
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P050037
Device type
- Device type
- Implant, dermal, for aesthetic use (LMH)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE ADDITION OF SAFETY AND EFFECTIVENESS CLINICAL DATA AND POST-MARKETING SURVEILLANCE DATA FROM THE POST APPROVAL STUDIES PERFORMED AS A CONDITION OF APPROVAL FOR THE RADIESSE INJECTABLE IMPLANT. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THETRADE NAME RADIESSE INJECTABLE IMPLANT AND IS INDICATED FOR SUBDERMAL IMPLANTATION FOR THE CORRECTION OF MODERATE TO SEVERE FACIAL WRINKLES AND FOLDS, SUCH AS NASOLABIAL FOLDS AND IT IS ALSO INTENDED FOR RESTORATION AND/OR CORRECTION OF THE SIGNS OF FACIAL FAT LOSS (LIPOATROPHY) IN PEOPLE WITH HUMAN IMMUNODEFICIENCY VIRUS.
Source documents
Other decisions for Merz North America, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250016 · Decided Jul 9, 2026 · 387 days after receipt
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
6 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.